Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dasatinib plus chemotherapy for newly diagnosed pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia
jRCTs041190067Phase 2Active, not recruiting
- Sponsor
- Japan Agency for Medical Research and Development
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of dasatinib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Japan Agency for Medical Research and Development. Primary endpoints: 3-year event-free survival and Transplantation avoidance rate in first complete remission. Started Oct 2019; status: active, not recruiting.
02
Drugs
dasatinib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on jRCTs041190067.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190067.